{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:09:32Z","timestamp":1758931772432,"version":"3.44.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,26]]},"DOI":"10.7759\/cureus.93284","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T14:01:32Z","timestamp":1758895292000},"source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic Insights Into the Cardioprotective Effects of Modern Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mounica","family":"Ratnala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loveleen K","family":"Johal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulaihat F","family":"Galadima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima F","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine S","family":"Trejos Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirshan","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryem","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Usman","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia U","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, et al.. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020, 21:6275. 10.3390\/ijms21176275","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.35.2.260","article-title":"Recent updates on vascular complications in patients with type 2 diabetes mellitus","volume":"35","author":"Jung CH","year":"2020","unstructured":"Jung CH, Mok JO. Recent updates on vascular complications in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2020, 35:260-71. 10.3803\/EnM.2020.35.2.260","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-017-0225-1","article-title":"Cardiovascular risk assessment in patients with diabetes","volume":"9","author":"Bertoluci MC","year":"2017","unstructured":"Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017, 9:25. 10.1186\/s13098-017-0225-1","journal-title":"Diabetol Metab Syndr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s41745-023-00357-w","article-title":"The evolution of diabetes treatment through the ages: From starvation diets to insulin, incretins, SGLT2 inhibitors and beyond","volume":"103","author":"Mudaliar S","year":"2023","unstructured":"Mudaliar S. The evolution of diabetes treatment through the ages: From starvation diets to insulin, incretins, SGLT2 inhibitors and beyond. J Indian Inst Sci. 2023, 103:123-33. 10.1007\/s41745-023-00357-w","journal-title":"J Indian Inst Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.056","article-title":"Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC Focus Seminar","volume":"75","author":"Wilcox T","year":"2020","unstructured":"Wilcox T, De Block C, Schwartzbard AZ, Newman JD. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC Focus Seminar. J Am Coll Cardiol. 2020, 75:1956-74. 10.1016\/j.jacc.2020.02.056","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013650.pub2","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: A network meta-analysis","volume":"10","author":"Kanie T","year":"2021","unstructured":"Kanie T, Mizuno A, Takaoka Y, et al.. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: A network meta-analysis. Cochrane Database Syst Rev. 2021, 10:CD013650. 10.1002\/14651858.CD013650.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01575-9","article-title":"Cardiovascular outcomes trials: A paradigm shift in the current management of type 2 diabetes","volume":"21","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferovi\u0107 PM, Wanner C. Cardiovascular outcomes trials: A paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022, 21:144. 10.1186\/s12933-022-01575-9","journal-title":"Cardiovasc Diabetol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042155","article-title":"Heart failure endpoints in cardiovascular outcome trials of SGLT2 inhibitors in patients with type 2 diabetes: A critical evaluation of clinical and regulatory issues","volume":"140","author":"Butler J","year":"2019","unstructured":"Butler J, Packer M, Greene SJ, et al.. Heart failure endpoints in cardiovascular outcome trials of SGLT2 inhibitors in patients with type 2 diabetes: A critical evaluation of clinical and regulatory issues. Circulation. 2019, 140:2108-18. 10.1161\/CIRCULATIONAHA.119.042155","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: Using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: Using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02294-z","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure","volume":"23","author":"Wang DD","year":"2024","unstructured":"Wang DD, Naumova AV, Isquith D, et al.. Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Cardiovasc Diabetol. 2024, 23:197. 10.1186\/s12933-024-02294-z","journal-title":"Cardiovasc Diabetol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030395","article-title":"Effects of liraglutide, empagliflozin and their combination on left atrial strain and arterial function","volume":"60","author":"Katogiannis K","year":"2024","unstructured":"Katogiannis K, Thymis J, Kousathana F, et al.. Effects of liraglutide, empagliflozin and their combination on left atrial strain and arterial function. Medicina (Kaunas). 2024, 60:395. 10.3390\/medicina60030395","journal-title":"Medicina (Kaunas)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247939","article-title":"Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial","volume":"16","author":"Top WM","year":"2021","unstructured":"Top WM, Lehert P, Schalkwijk CG, Stehouwer CD, Kooy A. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. PLoS One. 2021, 16:e0247939. 10.1371\/journal.pone.0247939","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2023.2240130","article-title":"Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction","volume":"79","author":"Afshani MR","year":"2024","unstructured":"Afshani MR, Torfi E, Akiash N, Jahanshahi A, Mohamadi A, Sherafat O. Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction. Acta Cardiol. 2024, 79:419-25. 10.1080\/00015385.2023.2240130","journal-title":"Acta Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial","volume":"18","author":"Bizino MB","year":"2019","unstructured":"Bizino MB, Jazet IM, Westenberg JJ, van Eyk HJ, Paiman EH, Smit JW, Lamb HJ. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial. Cardiovasc Diabetol. 2019, 18:55. 10.1186\/s12933-019-0857-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01228-3","article-title":"A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: The ASSET study","volume":"20","author":"Hiruma S","year":"2021","unstructured":"Hiruma S, Shigiyama F, Hisatake S, et al.. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: The ASSET study. Cardiovasc Diabetol. 2021, 20:32. 10.1186\/s12933-021-01228-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.12.015","article-title":"Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLE","volume":"19","author":"Emanuelsson F","year":"2025","unstructured":"Emanuelsson F, Jensen J, Omar M, et al.. Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLE. J Clin Lipidol. 2025, 19:276-85. 10.1016\/j.jacl.2024.12.015","journal-title":"J Clin Lipidol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2174\/0115748871323540241212060946","article-title":"Empagliflozin ameliorates the oxidative stress profile in type 2 diabetic patients with heart failure and reduced ejection fraction: Results of a randomized, double-blind, placebo-controlled study","volume":"20","author":"Eshraghi A","year":"2025","unstructured":"Eshraghi A, Khalesi S, Amini K, et al.. Empagliflozin ameliorates the oxidative stress profile in type 2 diabetic patients with heart failure and reduced ejection fraction: Results of a randomized, double-blind, placebo-controlled study. Rev Recent Clin Trials. 2025, 20:167-79. 10.2174\/0115748871323540241212060946","journal-title":"Rev Recent Clin Trials"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2016.08.011","article-title":"Effect of sitagliptin on plaque changes in coronary artery following acute coronary syndrome in diabetic patients: The ESPECIAL-ACS study","volume":"69","author":"Kuramitsu S","year":"2017","unstructured":"Kuramitsu S, Miyauchi K, Yokoi H, et al.. Effect of sitagliptin on plaque changes in coronary artery following acute coronary syndrome in diabetic patients: The ESPECIAL-ACS study. J Cardiol. 2017, 69:369-76. 10.1016\/j.jjcc.2016.08.011","journal-title":"J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115686","article-title":"Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications","volume":"168","author":"Vaziri Z","year":"2023","unstructured":"Vaziri Z, Saleki K, Aram C, Alijanizadeh P, Pourahmad R, Azadmehr A, Ziaei N. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomed Pharmacother. 2023, 168:115686. 10.1016\/j.biopha.2023.115686","journal-title":"Biomed Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030313","article-title":"Cardiac fibrosis: Mechanistic discoveries linked to SGLT2 inhibitors","volume":"18","author":"Rolski F","year":"2025","unstructured":"Rolski F, M\u0105czewski M. Cardiac fibrosis: Mechanistic discoveries linked to SGLT2 inhibitors. Pharmaceuticals (Basel). 2025, 18:313. 10.3390\/ph18030313","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092450","article-title":"Malondialdehyde, antioxidant defense system components and their relationship with anthropometric measures and lipid metabolism biomarkers in apparently healthy women","volume":"11","author":"\u010cerniauskas L","year":"2023","unstructured":"\u010cerniauskas L, Ma\u017eeikien\u0117 A, Mazgelyt\u0117 E, Petrylait\u0117 E, Linkevi\u010di\u016bt\u0117-Dum\u010d\u0117 A, Burokien\u0117 N, Kar\u010diauskait\u0117 D. Malondialdehyde, antioxidant defense system components and their relationship with anthropometric measures and lipid metabolism biomarkers in apparently healthy women. Biomedicines. 2023, 11:2450. 10.3390\/biomedicines11092450","journal-title":"Biomedicines"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s44324-025-00068-z","article-title":"SGLT2 inhibitors across various patient populations in the era of precision medicine: The multidisciplinary team approach","volume":"3","author":"McLean P","year":"2025","unstructured":"McLean P, Bennett J, \u201cTrey\u201d Woods E, et al.. SGLT2 inhibitors across various patient populations in the era of precision medicine: The multidisciplinary team approach. NPJ Metab Health Dis. 2025, 3:29. 10.1038\/s44324-025-00068-z","journal-title":"NPJ Metab Health Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13030728","article-title":"Targeting diabetic atherosclerosis: The role of GLP-1 receptor agonists, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists in vascular protection and disease modulation","volume":"13","author":"Rroji M","year":"2025","unstructured":"Rroji M, Spahia N, Figurek A, Spasovski G. Targeting diabetic atherosclerosis: The role of GLP-1 receptor agonists, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists in vascular protection and disease modulation. Biomedicines. 2025, 13:728. 10.3390\/biomedicines13030728","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/410317-mechanistic-insights-into-the-cardioprotective-effects-of-modern-glucose-lowering-drugs-in-type-2-diabetes-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T14:01:33Z","timestamp":1758895293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/410317-mechanistic-insights-into-the-cardioprotective-effects-of-modern-glucose-lowering-drugs-in-type-2-diabetes-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.93284","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}